Chengdu Kanghong Pharmaceutical Group Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Xiao Ke

Algemeen directeur

CN¥2.0m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	14.4yrs
Eigendom CEO	8.7%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	6.5yrs

Recente managementupdates

Recent updates

Insufficient Growth At Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) Hampers Share Price

Sep 15

Here's Why We Think Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Is Well Worth Watching

Jun 21

Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Price Is Right But Growth Is Lacking After Shares Rocket 40%

May 12

Lacklustre Performance Is Driving Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Low P/E

Mar 27

CEO

Xiao Ke (41 yo)

14.4yrs

Tenure

CN¥2,045,500

Compensatie

Mr. Xiao Ke serves as a General Manager and President of Chengdu Kanghong Pharmaceuticals Group Co., Ltd., and Director since June 21, 2010 and served as Vice President.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Xiao Ke	GM, President & Director	14.4yrs	CN¥2.05m	8.73% CN¥ 1.6b
Jin Qun Yin	VP & Director	8.2yrs	CN¥5.85m	0.038% CN¥ 6.9m
Jian Rong Zhong	VP & Director	16.4yrs	CN¥1.43m	1.15% CN¥ 208.9m
Lin Wang	Non-Independent Director	13.4yrs	geen gegevens	geen gegevens
Demin Zhou	Independent Director	1.3yrs	CN¥50.00k	geen gegevens
Zhirong Zhang	Non-Independent Director	1.3yrs	geen gegevens	geen gegevens
Jian Qun Yang	Employee Representative Supervisor	4.9yrs	geen gegevens	0.0016% CN¥ 296.1k
Zun Hong Ke	Chairman of the Board	23.8yrs	CN¥1.32m	22.58% CN¥ 4.1b
Wen Xian Gong	Chairman of the Supervisory Board	13.4yrs	geen gegevens	3.55% CN¥ 644.4m
Yin Ying Yang	Employee Supervisor	4.9yrs	geen gegevens	geen gegevens
Hongguang Deng	Independent Director	1.3yrs	CN¥50.00k	geen gegevens
Nan Xu	Independent Director	1.3yrs	CN¥50.00k	geen gegevens

6.5yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002773 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.5 jaar).

Chengdu Kanghong Pharmaceutical Group Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Chengdu Kanghong Pharmaceutical Group Co., Ltd, Annual General Meeting, May 16, 2024

Insufficient new directors

High number of new directors

Chengdu Kanghong Pharmaceutical Group Co., Ltd, Annual General Meeting, May 20, 2022

High number of new directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.31 (vs CN¥0.33 in 3Q 2023)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 16%

Insufficient Growth At Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) Hampers Share Price

Second quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.27 in 2Q 2023)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 23, 2024

Here's Why We Think Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Is Well Worth Watching

Dividend increased to CN¥0.38

Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Price Is Right But Growth Is Lacking After Shares Rocket 40%

Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023

Chengdu Kanghong Pharmaceutical Group Co., Ltd, Annual General Meeting, May 16, 2024

Investor sentiment improves as stock rises 17%

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.30 in 1Q 2023)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 25, 2024

Lacklustre Performance Is Driving Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Low P/E

Investor sentiment improves as stock rises 19%

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: CN¥0.33 (vs CN¥0.24 in 3Q 2022)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.26 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on Share A for 2022, Payable on June 6, 2023

Investor sentiment improves as stock rises 15%

Insufficient new directors

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.25 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.21 in 2Q 2021)

Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Cash Dividend for A Shares for the Year 2021, Payment date is 08 June 2022

Chengdu Kanghong Pharmaceutical Group Co. Ltd. Approves Cash Dividend for the Year 2021

Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2021

Chengdu Kanghong Pharmaceutical Group Co., Ltd, Annual General Meeting, May 20, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Third quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.28 in 3Q 2020)

High number of new directors

Second quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.18 in 2Q 2020)

Price target decreased to CN¥41.62

First quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.20 in 1Q 2020)

Chengdu Kanghong Pharmaceuticals Group Co., Proposes Final Cash Dividend for the Year 2020

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥35.28

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.82 in FY 2019)

Earnings beat expectations, revenue disappoints

Chengdu Kanghong Pharmaceutical Group Receives Special Protocol Assessments from the Food and Drug Administration for Three New Indications for Its Biologic Drug Conbercept

New 90-day low: CN¥35.44

New 90-day low: CN¥39.81

Price target raised to CN¥51.95

Investor sentiment improved over the past week

New 90-day high: CN¥47.89

Chengdu Kanghong Pharmaceuticals Group Co., Ltd Announces Completion 36-Week Primary Endpoint Visits of Phase Iii Trial of Conbercept

New 90-day low: CN¥39.85

Third-quarter earnings released: Earnings beat expectations, revenue disappoints

Third quarter earnings released

Chengdu Kanghong Pharmaceuticals Group Co., Ltd to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥42.93

New 90-day high - CN¥51.18

Earnings released

Chengdu Kanghong Pharmaceuticals Group Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd